KA Sauter, LJ Wood, J Wong… - Cancer biology & …, 2011 - ncbi.nlm.nih.gov Anthracyclines including doxorubicin and daunorubicin are commonly used for the treatment of both hematologic and solid tumors. Dose related adverse effects often limit the effectiveness of anthracyclines in chemotherapy. Drug-related systemic inflammation mediated by ... All 5 versions
HP Kim, B Gerhard, TO Harasym, LD Mayer… - Experimental …, 2011 - Elsevier AML blasts and progenitors from patients who achieved complete remission were more sensitive to both CPX-351 and free drugs than the same cells from patients with chemotherapy refractory leukemia. However, AML CFC and CD34 + CD38 - AML blasts (enriched for candidate ... All 2 versions
[HTML] from hematologylibrary.orgS Ohtake, S Miyawaki, H Fujita… - …, 2011 - bloodjournal.hematologylibrary.org We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin would be as effective as standard-dose idarubicin in remission-induction therapy for newly diagnosed adult patients younger than 65 years of age with acute myeloid leukemia. Of 1064 ... Cited by 13 - Related articles - All 4 versions
MR Baer, SL George, BL Sanford, K Mrózek… - Leukemia, 2011 - nature.com Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients 60 years received intensified chemotherapy, including daunorubicin 60 mg/m 2 and etoposide 100 mg/m 2 during days 1, 2, 3 with cytarabine 100 mg/m 2 during days 1–7, with a second ... Cited by 3 - Related articles - All 4 versions
L Zhong, H Shen, C Huang, H Jing… - Toxicology and applied …, 2011 - ncbi.nlm.nih.gov Daunorubicin, idarubicin, doxorubicin and epirubicin are anthracyclines widely used for the treatment of lymphoma, leukemia, and breast, lung, and liver cancers, but tumor resistance limits their clinical success. Aldo-keto reductase family 1 B10 (AKR1B10) is an NADPH-dependent enzyme ...
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
